Cardio Catch-Up: Registry Data Spurs Discussion On TAVR For Asymptomatic Patients
Executive Summary
Results from the TVT Registry suggest that TAVR may benefit patients who have severe aortic disease but few symptoms. Clinical trials specifically designed to answer that question are needed, according to an editorial in JACC
You may also be interested in...
Exec Chat: Medtronic’s Goodheart Talks About COVID, AI, Diversity, TAVR And More
Medtech Insight sat down with Nina Goodheart, the president of Medtronic’s structural heart and aortic operating unit, to learn more about her experience with the company during the pandemic, the company’s commitment to diversity and inclusion, and the future of structural heart technology.
“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business
Nevro is known for its spinal cord stimulation technology but wants to help a wide range of patients with chronic pain, so it is buying Vyrsa, which offers a complete system for sacroiliac joint fusion. In and interview with Medtech Insight, Nevro CEO Kevin Thornal explained how Vyrsa supports Nevro's strategy in this growing market.
News We’re Watching: New AF Guidelines, Nevro Buys Vyrsa, LivaNova Responds To Cyberattack
Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks. Last week, cardiologists got new guidelines for managing patients with atrial fibrillation and Nevro made a big move to expand beyond its core spinal cord stimulation business.